Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Supernus Pharmaceuticals (SUPN – Research Report) and Vaxcyte (PCVX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Supernus Pharmaceuticals (SUPN)
In a report released yesterday, Stacy Ku from TD Cowen maintained a Buy rating on Supernus Pharmaceuticals, with a price target of $65.00. The company’s shares closed last Tuesday at $53.30.
According to TipRanks.com, Ku is a 4-star analyst with an average return of
Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $62.17.
See Insiders’ Hot Stocks on TipRanks >>
Vaxcyte (PCVX)
In a report released yesterday, Tara Bancroft from TD Cowen maintained a Buy rating on Vaxcyte, with a price target of $75.00. The company’s shares closed last Tuesday at $61.35, close to its 52-week low of $58.10.
According to TipRanks.com, Bancroft is a 5-star analyst with an average return of
Vaxcyte has an analyst consensus of Strong Buy, with a price target consensus of $96.50, implying a 59.0% upside from current levels. In a report issued on February 12, BTIG also maintained a Buy rating on the stock with a $85.00 price target.
